Pembrolizumab is a humanized antibody that targets programmed cell death receptor-1. This agent is approved for use in the treatment of several malignancies. While pruritus and papulo-erythematous rash are not uncommon with its use, severe reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis are very rare. We present herein a case of Stevens-Johnson syndrome occurring in a patient who had previously tolerated pembrolizumab without significant side effects for seven months. Prompt recognition of Stevens-Johnson syndrome/toxic epidermal necrolysis and discontinuation of the offending agent are paramount to ensure a favorable outcome.
ShindiapinaPAlinariL. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. Ther Adv Hematol2018; 9: 89–105.
GoldinerSSteigerPMeierBet al.Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res2016; 22: 4023–4029.
4.
FakoyaAOmenyiPAnthonyPet al.Stevens-Johnson syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci2018; 6: 730–738.
5.
ThebeauMRubinKHofmannMet al.Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: a nursing perspective. J Am Assoc Nurse Pract2017; 29: 294–303.
6.
KumarRDasADasS. Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines. Indian J Dermatol2018; 63: 117–124.
7.
BuchbinderEDesaiA. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol2016; 39: 89–106.
